Gilead Sciences
About Gilead Sciences
At Gilead, our purpose is to create a healthier world for all people. For the past 35+ years, Gilead has set and achieved bold ambitions in our fight against the world’s most devastating diseases. Our ambitions have yielded a cure for hepatitis C, revolutionary improvements in HIV treatment and prevention, as well as advancements in therapies for viral diseases and certain cancers.
We continue to confront the biggest public health challenges of our day by investing in world-class science, addressing societal barriers to care, and building a culture where our employees can make a real impact together.
Scientific Innovation
We have a strong and diversified pipeline along with a growing portfolio of marketed therapies. Through our pioneering internal discovery and development efforts plus our extensive network of partnerships, we intend to deliver 10+ transformative medicines by 2030.
- HIV: We have long been an innovator in HIV treatment and prevention, helping transform an inevitably fatal condition to a chronic one that can be well managed. Gilead also introduced the first once-daily oral medication for pre-exposure prophylaxis (PrEP) to help prevent HIV transmission.
- Liver Disease: We have transformed hepatitis C from a chronic condition into one that can be cured for millions of people, and we are providing options for people with hepatitis B and D. Beyond viral hepatitis, our goal is to deliver best-in-disease treatment for people living with primary biliary cholangitis, a chronic autoimmune liver disease, and for those with advanced Metabolic DysfunctionAssociated Steatohepatitis (MASH).
- Oncology: We have built a world-class oncology portfolio, together with Kite, which includes some of the most promising targets in cancer treatment today.
- Inflammation: We are building our inflammation portfolio through institutional partnerships and our own exceptional team of immunologists.
- COVID-19: We delivered the first approved treatment for COVID-19, now available in 170+ countries. Our research and preparation for future public health crises is ongoing.
Access and Health Equity
Our focus goes beyond medicine. We know that our innovation will have the most impact on patients when we collaborate with communities around the world to expand access, improve health equity and fulfill our responsibilities as a corporate citizen.
- We are committed to broad patient reach through pioneering access programs that touch all parts of the healthcare ecosystem.
- $325 million in funding provided to community partners in 2023.
- #1 global philanthropic funder of HIV causes.
- 127 resource-limited countries partner with us on disease awareness and building sustainable health systems.
People and Culture
Our 18,000+ employees around the world are our greatest asset. We are committed to creating an inclusive workplace that reflects the diversity of the communities we serve and empowers everyone to share bold ideas.
- More than half of our workforce is actively engaged in Employee Resource Groups, which support recruiting, professional development, culture-building, business impact and community cultivation.
- $8 million donated in 2023 to support STEM education, social services, and sustainability in our local communities.
- $15 million in donation matching contributed to causes our employees care about in 2023.
NHCSL BBA Contact
Andrew Zingale
Director State Government Affairs – California
Andrew.Zingale@Gilead.com
Learn More
Visit www.gilead.com to learn more.